Nyaradzo Mavis Mgodi, (MBChB, MMed) is a clinical pathologist with over 10 years of experience conducting HIV clinical trials in women of reproductive age in sub-Saharan Africa, including Zimbabwe, the home of the University of Zimbabwe-Clinical Trials Research Centre, a DAIDS Clinical Trials Unit (CTU). As the lead investigator in Harare, she has overseen the implementation of several HPTN studies (HPTN 076, HPTN 082, HPTN 084) and the Microbicide Trials Network (MTN) studies assessing safety and effectiveness of oral PrEP and the dapivirine vaginal ring.
She is protocol co-chairperson for HVTN 703/HPTN 081 study, also known as Antibody Mediated Prevention (AMP) and of MTN 025/HOPE study. Nyaradzo serves as a member of the HPTN Executive Committee, as a scientific reviewer for the Medical Research Council of Zimbabwe, and has served as a technical advisor for the Zimbabwe Population-based HIV Impact Assessment (ZIMPHIA) survey. She is a member of the Policy and Implementation Steering Committee for the Global Evaluation of Microbicide Sensitivity (GEMS) project, HIVR4P Program Organizing Committee and also served as Conference Advisory Committee member for International AIDS Society (IAS) 2017.
